DOCSLIB.ORG

Curriculum Vitae Steven Richard Meshnick, MD, Ph.D Birthdate: 4 April 1952

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Curriculum Vitae Steven Richard Meshnick, MD, Ph.D Birthdate: 4 April 1952 Curriculum Vitae Steven Richard Meshnick, MD, Ph.D Birthdate: 4 April 1952 A. Education and Training Institution and Location Degree Completion Date Field of Study Columbia College, New York, NY AB 05/1972 Biochemistry Rockefeller University, New York, NY PHD 06/1978 Medical Biochemistry Cornell University, New York, NY MD 06/1979 Medicine B. Positions and Honors Positions and Employment 1978 - 1978 Visiting Scientist, International Laboratory for Research in Animal Diseases, Nairobi 1979 - 1980 Assistant Professor, Rockefeller University., New York, NY 1980 - 1985 Assistant Professor, Cornell University Medical College, New York, NY 1985 - 1992 Associate Medical Professor, City University of New York Medical School, New York, NY 1992 - 1996 Associate Professor, University of Michigan School of Public Health, Ann Arbor, MI 1996 - 2001 Professor, University of Michigan School of Public Health, Ann Arbor, MI 1999 - 1999 Fulbright Fellow and Academic Visitor, University of Oxford, Wellcome Trust Centre for the Epidemiology of Infectious Diseases, Ocford 2001 - Professor, University of North Carolina Gillings School of Global Public Health, Chapel Hill, NC 2006 - Director, Epidemiology PhD program, University of North Carolina Gillings School of Global Public Health, Chapel Hill, NC 2012 - Associate Chair, Depatment of Epidemology, University of North Carolina Gillings School of Global Public Health, Chapel Hill, NC Other Experience and Professional Memberships 1974 - Member, American Society of Tropical Medicine and Hygiene 1988 - Editorial Board, American Journal of Tropical Medicine and Hygiene 2000 - Editorial Board, Journal of Infectious Diseases 2008 - Editoral Board, Journal of Clinical Medicine 2010 - 2015 Member, NIH Study Section, Clinical Research and Field Studies (CRFS) 2014 – Editorial Board, Malaria Journal Honors UK-US Fulbright, Fulbright Scholar 1999 Publications [1-94][95-313] 1 1. Meshnick, S.R., K.P. Chang, and A. Cerami, Heme lysis of the bloodstream forms of Trypanosoma brucei. Biochem Pharmacol, 1977. 26(20): p. 1923-8. 2. Steiger, R.F. and S.R. Meshnick, Amino-acid and glucose utilization of Leishmania donovani and L. braziliensis. Trans R Soc Trop Med Hyg, 1977. 71(5): p. 441-3. 3. Meshnick, S.R., S.H. Blobstein, R.W. Grady, and A. Cerami, An approach to the development of new drugs for African trypanosomiasis. J Exp Med, 1978. 148(2): p. 569-79. 4. Meshnick, S.R., R.W. Grady, S.H. Blobstein, and A. Cerami, Porphyrin-induced lysis of Trypanosoma brucei: a role for zinc. J Pharmacol Exp Ther, 1978. 207(3): p. 1041-50. 5. Blobstein, S.H., R.W. Grady, S.R. Meshnick, and A. Cerami, Hydroxamic acid oxidation--pharmacological considerations. Biochem Pharmacol, 1978. 27(24): p. 2939-45. 6. McGuire, T.C., A.F. Barbet, H. Hirumi, S. Meshnick, and J.J. Doyle, Trypanosoma brucei: radioimmunoassay of variant surface glycoproteins from organisms grown in vitro and in vivo. Exp Parasitol, 1980. 50(2): p. 233-9. 7. Meshnick, S.R. and J.W. Eaton, Leishmanial superoxide dismutase: a possible target for chemotherapy. Biochem Biophys Res Commun, 1981. 102(3): p. 970- 6. 8. Fairfield, A.S., S.R. Meshnick, and J.W. Eaton, Malaria parasites adopt host cell superoxide dismutase. Science, 1983. 221(4612): p. 764-6. 9. Le Trant, N., S.R. Meshnick, K. Kitchener, J.W. Eaton, and A. Cerami, Iron- containing superoxide dismutase from Crithidia fasciculata. Purification, characterization, and similarity to Leishmanial and trypanosomal enzymes. J Biol Chem, 1983. 258(1): p. 125-30. 10. Fairfield, A.S., S.R. Meshnick, and J.W. Eaton, Host superoxide dismutase incorporation by intraerythrocytic plasmodia. Prog Clin Biol Res, 1984. 155: p. 13-23. 11. Grady, R.W., S.H. Blobstein, S.R. Meshnick, P.C. Ulrich, A. Cerami, J. Amirmoazzami, and E.M. Hodnett, The in vitro trypanocidal activity of N- substituted p-benzoquinone imines: assessment of biochemical structure-activity relationships using the Hansch approach. J Cell Biochem, 1984. 25(1): p. 15-29. 12. Kazura, J.W. and S.R. Meshnick, Scavenger enzymes and resistance to oxygen mediated damage in Trichinella spiralis. Mol Biochem Parasitol, 1984. 10(1): p. 1-10. 13. Kitchener, K.R., S.R. Meshnick, A.S. Fairfield, and C.C. Wang, An iron- containing superoxide dismutase in Tritrichomonas foetus. Mol Biochem Parasitol, 1984. 12(1): p. 95-9. 14. Meshnick, S.R., Recent studies on inhibitors of macromolecular synthesis and function in trypanosomes. Pharmacol Ther, 1984. 25(2): p. 239-54. 15. Meshnick, S.R., D. Brown, and G. Smith, Capacity of a cis-diammineplatinum[II]- polyglutamic acid complex to cure Trypanosoma congolense infections in mice. Antimicrob Agents Chemother, 1984. 25(2): p. 286-8. 2 16. Hrushesky, W.J., R. Olshefski, P. Wood, S. Meshnick, and J.W. Eaton, Modifying intracellular redox balance: an approach to improving therapeutic index. Lancet, 1985. 1(8428): p. 565-7. 17. Meshnick, S.R., K.R. Kitchener, and N.L. Trang, Trypanosomatid iron-superoxide dismutase inhibitors. Selectivity and mechanism of N1,N6-bis(2,3- dihydroxybenzoyl)-1,6-diaminohexane. Biochem Pharmacol, 1985. 34(17): p. 3147-52. 18. Meshnick, S.R., Molecular pharmacology of protozoan parasites. Parasitol Today, 1986. 2(8): p. 221-3. 19. Fairfield, A.S., J.W. Eaton, and S.R. Meshnick, Superoxide dismutase and catalase in the murine malaria, Plasmodium berghei: content and subcellular distribution. Arch Biochem Biophys, 1986. 250(2): p. 526-9. 20. Scott, M.D., S.R. Meshnick, and J.W. Eaton, Superoxide dismutase-rich bacteria. Paradoxical increase in oxidant toxicity. J Biol Chem, 1987. 262(8): p. 3640-5. 21. Fairfield, A.S., A. Abosch, A. Ranz, J.W. Eaton, and S.R. Meshnick, Oxidant defense enzymes of Plasmodium falciparum. Mol Biochem Parasitol, 1988. 30(1): p. 77-82. 22. Scott, M.D., S.R. Meshnick, R.A. Williams, D.T. Chiu, H.C. Pan, B.H. Lubin, and F.A. Kuypers, Qinghaosu-mediated oxidation in normal and abnormal erythrocytes. J Lab Clin Med, 1989. 114(4): p. 401-6. 23. Kwakye-Berko, F. and S.R. Meshnick, Binding of chloroquine to DNA. Mol Biochem Parasitol, 1989. 35(1): p. 51-5. 24. Meshnick, S.R. and J.W. Eaton, How to give a scientific talk. Prog Clin Biol Res, 1989. 319: p. 663-4. 25. Meshnick, S.R., T.W. Tsang, F.B. Lin, H.Z. Pan, C.N. Chang, F. Kuypers, D. Chiu, and B. Lubin, Activated oxygen mediates the antimalarial activity of qinghaosu. Prog Clin Biol Res, 1989. 313: p. 95-104. 26. Ranz, A. and S.R. Meshnick, Plasmodium falciparum: inhibitor sensitivity of the endogenous superoxide dismutase. Exp Parasitol, 1989. 69(2): p. 125-8. 27. Scott, M.D., S.R. Meshnick, and J.W. Eaton, Superoxide dismutase amplifies organismal sensitivity to ionizing radiation. J Biol Chem, 1989. 264(5): p. 2498- 501. 28. Merali, S., Y. Zhang, D. Sloan, and S. Meshnick, Inhibition of Pneumocystis carinii dihydropteroate synthetase by sulfa drugs. Antimicrob Agents Chemother, 1990. 34(6): p. 1075-8. 29. Meshnick, S.R., Chloroquine as intercalator: a hypothesis revived. Parasitol Today, 1990. 6(3): p. 77-9. 30. Meshnick, S.R., M.D. Scott, B. Lubin, A. Ranz, and J.W. Eaton, Antimalarial activity of diethyldithiocarbamate. Potentiation by copper. Biochem Pharmacol, 1990. 40(2): p. 213-6. 31. Scott, M.D., A. Ranz, F.A. Kuypers, B.H. Lubin, and S.R. Meshnick, Parasite uptake of desferroxamine: a prerequisite for antimalarial activity. Br J Haematol, 1990. 75(4): p. 598-602. 32. Bates, M.D., S.R. Meshnick, C.I. Sigler, P. Leland, and M.R. Hollingdale, In vitro effects of primaquine and primaquine metabolites on exoerythrocytic stages of Plasmodium berghei. Am J Trop Med Hyg, 1990. 42(6): p. 532-7. 3 33. Kwakye-Berko, F. and S. Meshnick, Sequence preference of chloroquine binding to DNA and prevention of Z-DNA formation. Mol Biochem Parasitol, 1990. 39(2): p. 275-8. 34. Zhang, Y. and S.R. Meshnick, Inhibition of Plasmodium falciparum dihydropteroate synthetase and growth in vitro by sulfa drugs. Antimicrob Agents Chemother, 1991. 35(2): p. 267-71. 35. Meshnick, S.R., A. Thomas, A. Ranz, C.M. Xu, and H.Z. Pan, Artemisinin (qinghaosu): the role of intracellular hemin in its mechanism of antimalarial action. Mol Biochem Parasitol, 1991. 49(2): p. 181-9. 36. Merali, S. and S.R. Meshnick, Susceptibility of Pneumocystis carinii to artemisinin in vitro. Antimicrob Agents Chemother, 1991. 35(6): p. 1225-7. 37. Hong, Y.L., H.Z. Pan, M.D. Scott, and S.R. Meshnick, Activated oxygen generation by a primaquine metabolite: inhibition by antioxidants derived from Chinese herbal remedies. Free Radic Biol Med, 1992. 12(3): p. 213-8. 38. Zhang, F., D.K. Gosser, Jr., and S.R. Meshnick, Hemin-catalyzed decomposition of artemisinin (qinghaosu). Biochem Pharmacol, 1992. 43(8): p. 1805-9. 39. Zhang, Y., S. Merali, and S.R. Meshnick, p-Aminobenzoic acid transport by normal and Plasmodium falciparum-infected erythrocytes. Mol Biochem Parasitol, 1992. 52(2): p. 185-94. 40. Yang, Y.Z., A. Ranz, H.Z. Pan, Z.N. Zhang, X.B. Lin, and S.R. Meshnick, Daphnetin: a novel antimalarial agent with in vitro and in vivo activity. Am J Trop Med Hyg, 1992. 46(1): p. 15-20. 41. Meshnick, S.R. and J.J. Marr, Intracellular parasites. New developments in chemotherapy. Subcell Biochem, 1992. 18: p. 401-41. 42. Yang, Y.Z., W. Asawamahasakda, and S.R. Meshnick, Alkylation of human albumin by the antimalarial artemisinin. Biochem Pharmacol, 1993. 46(2): p. 336- 9. 43. Nguyen, D.S., B.H. Dao, P.D. Nguyen, V.H. Nguyen, N.B. Le, V.S. Mai, and S.R. Meshnick, Treatment of malaria in Vietnam with oral artemisinin. Am J Trop Med Hyg, 1993. 48(3): p. 398-402. 44.
Load more

Recommended publications
  • Trypanocidal Activity of Ethanolic Leaf Extract of Andrographis Paniculata
    Science World Journal Vol. 15(No 4) 2020 www.scienceworldjournal.org ISSN: 1597-6343 (Online), ISSN: 2756-391X (Print) Published by Faculty of Science, Kaduna State University TRYPANOCIDAL ACTIVITY OF ETHANOLIC LEAF EXTRACT OF ANDROGRAPHIS PANICULATA 1* 2 3 4 Ladan Z., Olanrewaju T. O., Maikaje D.B., and Waziri P. N. Full Length Research Article 1Department of Chemistry, Kaduna State University, Kaduna, Nigeria 2Human African Trypanosomiasis Research Department, Nigerian Institute for Trypanosomiasis Research, Kaduna, Nigeria 3Department of Microbiology, Kaduna State University, Kaduna, Nigeria 4Department of Biochemistry, Kaduna State University, Kaduna, Nigeria *Corresponding Author’s Email Address: [email protected] Phone: 2347030475898 ABSTRACT animal Trypanosomiasis (Achenef and Bekele, 2013; Giordani et Andrographis paniculata used in this study belongs to Acanthacae al., 2016). Various industries are now on the search for sources of family and is commonly known as king of bitters. This study aimed alternative which include synthetic and natural products. Medicinal at evaluating effect of A. paniculata leaf extract on experimental plants remain a major source of alternative medicine and scientific rats infected with Trypanosoma brucei brucei. Cold maceration was investigations have shown that various plants indicate promising used for extraction and the biomass was fractionated in open results for the development of cheaper less toxic drugs for column chromatography. One of the ethanolic fractions obtained treatment and management of trypanosomiasis (Simoben et al., from A. paniculata was evaluated for in vitro and in vivo activities 2018). Andrographis paniculata evaluated in this study belong to using RPMI 1640 cell culture media and experimental wistar rats Acanthacae family of the plant kingdom and commonly known as respectively.
    [Show full text]
  • Eurartesim, INN-Piperaquine & INN-Artenimol
    ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT Eurartesim 160 mg/20 mg film-coated tablets. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each film-coated tablet contains 160 mg piperaquine tetraphosphate (as the tetrahydrate; PQP) and 20 mg artenimol. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Film-coated tablet (tablet). White oblong biconvex film-coated tablet (dimension 11.5x5.5mm / thickness 4.4mm) with a break-line and marked on one side with the letters “S” and “T”. The tablet can be divided into equal doses. 4. CLINICAL PARTICULARS 4.1 Therapeutic indications Eurartesim is indicated for the treatment of uncomplicated Plasmodium falciparum malaria in adults, adolescents, children and infants 6 months and over and weighing 5 kg or more. Consideration should be given to official guidance on the appropriate use of antimalarial medicinal products, including information on the prevalence of resistance to artenimol/piperaquine in the geographical region where the infection was acquired (see section 4.4). 4.2 Posology and method of administration Posology Eurartesim should be administered over three consecutive days for a total of three doses taken at the same time each day. 2 Dosing should be based on body weight as shown in the table below. Body weight Daily dose (mg) Tablet strength and number of tablets per dose (kg) PQP Artenimol 5 to <7 80 10 ½ x 160 mg / 20 mg tablet 7 to <13 160 20 1 x 160 mg / 20 mg tablet 13 to <24 320 40 1 x 320 mg / 40 mg tablet 24 to <36 640 80 2 x 320 mg / 40 mg tablets 36 to <75 960 120 3 x 320 mg / 40 mg tablets > 75* 1,280 160 4 x 320 mg / 40 mg tablets * see section 5.1 If a patient vomits within 30 minutes of taking Eurartesim, the whole dose should be re-administered; if a patient vomits within 30-60 minutes, half the dose should be re-administered.
    [Show full text]
  • Folic Acid Antagonists: Antimicrobial and Immunomodulating Mechanisms and Applications
    International Journal of Molecular Sciences Review Folic Acid Antagonists: Antimicrobial and Immunomodulating Mechanisms and Applications Daniel Fernández-Villa 1, Maria Rosa Aguilar 1,2 and Luis Rojo 1,2,* 1 Instituto de Ciencia y Tecnología de Polímeros, Consejo Superior de Investigaciones Científicas, CSIC, 28006 Madrid, Spain; [email protected] (D.F.-V.); [email protected] (M.R.A.) 2 Consorcio Centro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina, 28029 Madrid, Spain * Correspondence: [email protected]; Tel.: +34-915-622-900 Received: 18 September 2019; Accepted: 7 October 2019; Published: 9 October 2019 Abstract: Bacterial, protozoan and other microbial infections share an accelerated metabolic rate. In order to ensure a proper functioning of cell replication and proteins and nucleic acids synthesis processes, folate metabolism rate is also increased in these cases. For this reason, folic acid antagonists have been used since their discovery to treat different kinds of microbial infections, taking advantage of this metabolic difference when compared with human cells. However, resistances to these compounds have emerged since then and only combined therapies are currently used in clinic. In addition, some of these compounds have been found to have an immunomodulatory behavior that allows clinicians using them as anti-inflammatory or immunosuppressive drugs. Therefore, the aim of this review is to provide an updated state-of-the-art on the use of antifolates as antibacterial and immunomodulating agents in the clinical setting, as well as to present their action mechanisms and currently investigated biomedical applications. Keywords: folic acid antagonists; antifolates; antibiotics; antibacterials; immunomodulation; sulfonamides; antimalarial 1.
    [Show full text]
  • Pharmacological and Cardiovascular Perspectives on the Treatment of COVID-19 with Chloroquine Derivatives
    www.nature.com/aps REVIEW ARTICLE Pharmacological and cardiovascular perspectives on the treatment of COVID-19 with chloroquine derivatives Xiao-lei Zhang1, Zhuo-ming Li1, Jian-tao Ye1, Jing Lu1, Lingyu Linda Ye2, Chun-xiang Zhang3, Pei-qing Liu1 and Dayue D Duan2 The novel severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) causes coronavirus disease 2019 (COVID-19) and an ongoing severe pandemic. Curative drugs specific for COVID-19 are currently lacking. Chloroquine phosphate and its derivative hydroxychloroquine, which have been used in the treatment and prevention of malaria and autoimmune diseases for decades, were found to inhibit SARS-CoV-2 infection with high potency in vitro and have shown clinical and virologic benefits in COVID-19 patients. Therefore, chloroquine phosphate was first used in the treatment of COVID-19 in China. Later, under a limited emergency- use authorization from the FDA, hydroxychloroquine in combination with azithromycin was used to treat COVID-19 patients in the USA, although the mechanisms of the anti-COVID-19 effects remain unclear. Preliminary outcomes from clinical trials in several countries have generated controversial results. The desperation to control the pandemic overrode the concerns regarding the serious adverse effects of chloroquine derivatives and combination drugs, including lethal arrhythmias and cardiomyopathy. The risks of these treatments have become more complex as a result of findings that COVID-19 is actually a multisystem disease. While respiratory symptoms are the major clinical manifestations, cardiovascular abnormalities, including arrhythmias, myocarditis, heart failure, and ischemic stroke, have been reported in a significant number of COVID-19 patients. Patients with preexisting cardiovascular conditions (hypertension, arrhythmias, etc.) are at increased risk of severe COVID-19 and death.
    [Show full text]
  • Annual Review 2004 Contents Contentsforeword
    Annual Review 2004 Contents ContentsForeword ........................................................................................................................... 3 Editor’s Note ..................................................................................................................... 4 Organization Chart ............................................................................................................ 5 Administrative Board .......................................................................................................... 6 Special Events..................................................................................................................... 8 Consultants ...................................................................................................................... 13 Visiting Professors ............................................................................................................ 13 Faculty Board ...................................................................................................................13 Faculty Senate ..................................................................................................................14 Department of Clinical Tropical Medicine ........................................................................ 15 Department of Helminthology ......................................................................................... 22 Department of Medical Entomology ...............................................................................
    [Show full text]
  • Plasmodium Falciparum Clinical Isolates: in Vitro Genotypic and Phenotypic Characterization Nonlawat Boonyalai1* , Brian A
    Boonyalai et al. Malar J (2020) 19:269 https://doi.org/10.1186/s12936-020-03339-w Malaria Journal RESEARCH Open Access Piperaquine resistant Cambodian Plasmodium falciparum clinical isolates: in vitro genotypic and phenotypic characterization Nonlawat Boonyalai1* , Brian A. Vesely1, Chatchadaporn Thamnurak1, Chantida Praditpol1, Watcharintorn Fagnark1, Kirakarn Kirativanich1, Piyaporn Saingam1, Chaiyaporn Chaisatit1, Paphavee Lertsethtakarn1, Panita Gosi1, Worachet Kuntawunginn1, Pattaraporn Vanachayangkul1, Michele D. Spring1, Mark M. Fukuda1, Chanthap Lon1, Philip L. Smith2, Norman C. Waters1, David L. Saunders3 and Mariusz Wojnarski1 Abstract Background: High rates of dihydroartemisinin–piperaquine (DHA–PPQ) treatment failures have been documented for uncomplicated Plasmodium falciparum in Cambodia. The genetic markers plasmepsin 2 (pfpm2), exonuclease (pfexo) and chloroquine resistance transporter (pfcrt) genes are associated with PPQ resistance and are used for moni- toring the prevalence of drug resistance and guiding malaria drug treatment policy. Methods: To examine the relative contribution of each marker to PPQ resistance, in vitro culture and the PPQ survival assay were performed on seventeen P. falciparum isolates from northern Cambodia, and the presence of E415G-Exo and pfcrt mutations (T93S, H97Y, F145I, I218F, M343L, C350R, and G353V) as well as pfpm2 copy number polymor- phisms were determined. Parasites were then cloned by limiting dilution and the cloned parasites were tested for drug susceptibility. Isobolographic analysis of several drug combinations for standard clones and newly cloned P. falciparum Cambodian isolates was also determined. Results: The characterization of culture-adapted isolates revealed that the presence of novel pfcrt mutations (T93S, H97Y, F145I, and I218F) with E415G-Exo mutation can confer PPQ-resistance, in the absence of pfpm2 amplifcation.
    [Show full text]
  • Pharmaceutical Composition Comprising Artesunate
    (19) TZZ ¥ 4B_T (11) EP 2 322 244 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: A61P 33/06 (2006.01) A61K 9/20 (2006.01) 21.11.2012 Bulletin 2012/47 A61K 31/357 (2006.01) A61K 31/505 (2006.01) A61K 31/4965 (2006.01) (21) Application number: 10192206.0 (22) Date of filing: 09.09.2005 (54) Pharmaceutical composition comprising artesunate, sulfamethoxypyrazine and pyrimethamine suitable for the treatment of malaria within one day, in the form of a tablet Pharmazeutische Zusammensetzung enthaltend Artesunat, Sulfamethoxypyrazin und Pyrimethamin, die zur Behandlung von Malaria innerhalb eines Tages geeignet ist, in Form einer Tablette Composition pharmaceutique à base d’artesunate, de sulfaméthoxypyrazine et de pyriméthamine permettant le traitement du palludisme en un jour, sous forme de comprimé (84) Designated Contracting States: (56) References cited: AT BE BG CH CY CZ DE DK EE ES FI FR GB GR • LUXEMBURGER C ET AL: "Single day HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI mefloquine-artesunate combination in the SK TR treatment of multi-drug resistant falciparum malaria", TRANSACTIONS OF THE ROYAL (43) Date of publication of application: SOCIETY OF TROPICAL MEDICINE AND 18.05.2011 Bulletin 2011/20 HYGIENE, ELSEVIER, GB, vol. 88, no. 2, 1 March 1994 (1994-03-01), pages 213-217, XP023097868, (62) Document number(s) of the earlier application(s) in ELSEVIER, GB ISSN: 0035-9203, DOI: accordance with Art. 76 EPC: 10.1016/0035-9203(94)90303-4 [retrieved on 05795966.0 / 1 940 519 1994-03-01] • DAO ET AL: "Fatty food does not alter blood (73) Proprietor: Dafra Pharma N.V.
    [Show full text]
  • Downloaded and Saved in PDB Format
    bioRxiv preprint doi: https://doi.org/10.1101/833145; this version posted November 6, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. 1 Full title: Efficacy of Lumefantrine against piperaquine resistant Plasmodium berghei parasites is 2 selectively restored by probenecid, verapamil, and cyproheptadine through ferredoxin NADP+- 3 reductase and cysteine desulfurase 4 5 Short title: Mechanisms of Lumefantrine resistance and reversal in Plasmodium berghei ANKA 6 7 Authors: Fagdéba David Bara1,2,3, Loise Ndung’u1, Noah Machuki Onchieku1, Beatrice Irungu2, 8 Simplice Damintoti Karou3, Francis Kimani4, Damaris Matoke-Muhia4, Peter Mwitari2, Gabriel 9 Magoma1,5, Alexis Nzila6, Daniel Kiboi5* 10 11 Affiliations: 1Department of Molecular Biology and Biotechnology, Pan African University 12 Institute for Basic Sciences, Technology and Innovation (PAUSTI), Nairobi, Kenya. 2Centre for 13 Traditional Medicine and Drug Research, Kenya Medical Research Institute, Nairobi, Kenya. 14 3School of Food and Biology Technology, Universite du Lome, Lome, Togo. 4Centre for 15 Biotechnology Research and Development, Kenya Medical Research Institute, Nairobi, Kenya. 16 5Department of Biochemistry, Jomo Kenyatta University of Agriculture and Technology 17 (JKUAT), Nairobi, Kenya. 6Department of Life Sciences, King Fahd University of Petroleum and 18 Minerals, Dharam, Saudi Arabia. 19 20 Corresponding author: [email protected] ; [email protected] 1 bioRxiv preprint doi: https://doi.org/10.1101/833145; this version posted November 6, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
    [Show full text]
  • Treatment Failure Due to the Potential Under-Dosing of Dihydroartemisinin-Piperaquine in a Patient with Plasmodium Falciparum Uncomplicated Malaria
    INFECT DIS TROP MED 2019; 5: E525 Treatment failure due to the potential under-dosing of dihydroartemisinin-piperaquine in a patient with Plasmodium falciparum uncomplicated malaria I. De Benedetto1, F. Gobbi2, S. Audagnotto1, C. Piubelli2, E. Razzaboni3, R. Bertucci1, G. Di Perri1, A. Calcagno1 1Department of Medical Sciences, Unit of Infectious Diseases, University of Torino, Amedeo di Savoia Hospital, Torino, Italy 2Department of Infectious–Tropical Diseases and Microbiology, IRCCS Sacro Cuore Don Calabria Hospital, Verona, Italy 3Unit of Infectious Diseases, Azienda Ospedaliera Universitaria Integrata di Verona, Verona, Italy ABSTRACT: — Background: Dihydroartemisinin/piperaquine (DHA-PPQ) 40/320 mg is approved for the treatment of Plasmodium falciparum uncomplicated malaria. Different recommendations are provided by WHO guidelines and drug data sheet about dosing in overweight patients. We report here a treatment failure likely caused by sub-optimal dosing of dihydroartemisinin-piperaquine in a case of uncomplicated P. fal- ciparum malaria in a returning traveler from Burkina Faso. INTRODUCTION kg). They, therefore, provided an updated dosing body weight dosing schedule in their 2015 guidelines for Dihydroartemisinin/piperaquine (DHA-PPQ) 40/320 malaria treatment that provides for a dose of 200/1600 mg tablet formulation is approved for the treatment mg (5 tablets) in individuals > 80 kg1. of Plasmodium falciparum uncomplicated malaria in adults and children > 6 months and > 5 kg of body weight. Following WHO guidelines, the daily
    [Show full text]
  • Quinoline-Based Hybrid Compounds with Antimalarial Activity
    molecules Review Quinoline-Based Hybrid Compounds with Antimalarial Activity Xhamla Nqoro, Naki Tobeka and Blessing A. Aderibigbe * Department of Chemistry, University of Fort Hare, Alice Campus, Alice 5700, Eastern Cape, South Africa; [email protected] (X.N.); [email protected] (N.T.) * Correspondence: [email protected] Received: 7 November 2017; Accepted: 11 December 2017; Published: 19 December 2017 Abstract: The application of quinoline-based compounds for the treatment of malaria infections is hampered by drug resistance. Drug resistance has led to the combination of quinolines with other classes of antimalarials resulting in enhanced therapeutic outcomes. However, the combination of antimalarials is limited by drug-drug interactions. In order to overcome the aforementioned factors, several researchers have reported hybrid compounds prepared by reacting quinoline-based compounds with other compounds via selected functionalities. This review will focus on the currently reported quinoline-based hybrid compounds and their preclinical studies. Keywords: 4-aminoquinoline; 8-aminoquinoline; malaria; infectious disease; hybrid compound 1. Introduction Malaria is a parasitic infectious disease that is a threat to approximately half of the world’s population. This parasitic disease is transmitted to humans by a female Anopheles mosquito when it takes a blood meal. Pregnant women and young children in the sub-tropical regions are more prone to malaria infection. In 2015, 214 million infections were reported, with approximately 438,000 deaths and the African region accounted for 90% of the deaths [1–3]. Malaria is caused by five parasites of the genus Plasmodium, but the majority of deaths are caused by Plasmodium falciparum and Plasmodium vivax [1,4–6].
    [Show full text]
  • Part 4 May 2016 Sulfadoxine/Pyrimethamine 500Mg/25Mg, Tablets, (Guilin Pharmaceutical Co., Ltd), MA066
    Artesunate 50mg Tablets + WHOPAR part 4 May 2016 Sulfadoxine/Pyrimethamine 500mg/25mg, Tablets, (Guilin Pharmaceutical Co., Ltd), MA066 SUMMARY OF PRODUCT CHARACTERISTICS 1 Artesunate 50mg Tablets + WHOPAR part 4 May 2016 Sulfadoxine/Pyrimethamine 500mg/25mg, Tablets, (Guilin Pharmaceutical Co., Ltd), MA066 1. NAME OF THE MEDICINAL PRODUCT ARTECOSPE ® 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each artesunate tablet contains 50 mg artesunate, each sulfadoxine/pyrimethamine tablet contains 500 mg sulfadoxine and 25 mg pyrimethamine. Each artesunate tablet contains 15 mg of sucrose. Each sulfadoxine/pyrimethamine tablet contains 20 mg of lactose. For a full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM The artesunate 50 mg tablets are white round tablets debossed with “AS ” on one side and a score line on the other side. The sulfadoxine/pyrimethamine tablets (500/25 mg) are white, round, and debossed with “SP” on both sides, with a score line on one side. 4. CLINICAL PARTICULARS 4.1 Therapeutic indication ARTECOSPE® (artesunate + sulfadoxine/pyrimethamine) is indicated for the treatment of uncomplicated cases of malaria due to Plasmodium falciparum strains which are susceptible to artesunate as well as to sulfadoxine /pyrimethamine. The most recent official guidelines on the appropriate use of antimalarial agents and local information on the prevalence of resistance to antimalarial drugs must be taken into consideration for deciding on the appropriateness of therapy with artesunate tablets and sulfadoxine/pyrimethamine tablets. Official guidance will normally include WHO (http://apps.who.int/iris/bitstream/10665/162441/1/9789241549127_eng.pdf?ua=1&ua=1) and public health authorities’ guidelines (see also sections 4.4 and 5.1).
    [Show full text]
  • Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set
    MTC eHealth DSI [eHDSI v2.2.2-OR] eHealth DSI – Master Value Set Catalogue Responsible : eHDSI Solution Provider PublishDate : Wed Nov 08 16:16:10 CET 2017 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 1 of 490 MTC Table of Contents epSOSActiveIngredient 4 epSOSAdministrativeGender 148 epSOSAdverseEventType 149 epSOSAllergenNoDrugs 150 epSOSBloodGroup 155 epSOSBloodPressure 156 epSOSCodeNoMedication 157 epSOSCodeProb 158 epSOSConfidentiality 159 epSOSCountry 160 epSOSDisplayLabel 167 epSOSDocumentCode 170 epSOSDoseForm 171 epSOSHealthcareProfessionalRoles 184 epSOSIllnessesandDisorders 186 epSOSLanguage 448 epSOSMedicalDevices 458 epSOSNullFavor 461 epSOSPackage 462 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 2 of 490 MTC epSOSPersonalRelationship 464 epSOSPregnancyInformation 466 epSOSProcedures 467 epSOSReactionAllergy 470 epSOSResolutionOutcome 472 epSOSRoleClass 473 epSOSRouteofAdministration 474 epSOSSections 477 epSOSSeverity 478 epSOSSocialHistory 479 epSOSStatusCode 480 epSOSSubstitutionCode 481 epSOSTelecomAddress 482 epSOSTimingEvent 483 epSOSUnits 484 epSOSUnknownInformation 487 epSOSVaccine 488 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 3 of 490 MTC epSOSActiveIngredient epSOSActiveIngredient Value Set ID 1.3.6.1.4.1.12559.11.10.1.3.1.42.24 TRANSLATIONS Code System ID Code System Version Concept Code Description (FSN) 2.16.840.1.113883.6.73 2017-01 A ALIMENTARY TRACT AND METABOLISM 2.16.840.1.113883.6.73 2017-01
    [Show full text]